Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ResoTher Pharma

ResoTher Pharma?uq=kiHouaul
2016 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
1 INVESTORS
Description

Developer of peptide therapeutics intended to cardiovascular disorders. The company's peptide-based drugs direct against the FPR2 receptor as resolution therapy for diseases, enabling doctors to respond to inflammation and initiating tissue repair through their actions on the FPR2 receptor, a G-protein coupled receptor expressed on the surface of leukocytes.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Næsseslottet
  • Dronninggards Alle 136
  • 2840 Holte
  • Denmark

+45 41 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ResoTher Pharma’s full profile, request a free trial.

ResoTher Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

ResoTher Pharma Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Capnova Venture Capital Minority 000 0000 000000 0

ResoTher Pharma Executive Team (3)

Name Title Board
Seat
Contact
Info
Lone Veng Ph.D Chief Executive Officer
Thomas Jonassen MD Chief Science Officer
Jeppe Øvlesen Chief Financial Officer & Board Member

ResoTher Pharma Board Members (4)

Name Representing Role Since Contact
Info
Henrik Stage Self Board Member 000 0000
Jeppe Øvlesen Self Chief Financial Officer & Board Member 000 0000
Kirsten Drejer Ph.D Self Board Member 000 0000
Mette Munch Ph.D Capnova Board Member 000 0000